{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:58:32Z","timestamp":1776412712239,"version":"3.51.2"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.msard.2021.102945","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:01:48Z","timestamp":1618358508000},"page":"102945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-6348","authenticated-orcid":false,"given":"Gauruv","family":"Bose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Rush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold L.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102945_bib0001","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102945_bib0002","unstructured":"Center for Drug Evaluation and Research, Food and Drug Administration, 2019. Treatment of Relapsing forms of Multiple Sclerosis (RMS). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/022561Orig1s000ClinPharmR.pdf."},{"issue":"5","key":"10.1016\/j.msard.2021.102945_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/1352458519887324","article-title":"Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment","volume":"26","author":"Bose","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102945_bib0003","first-page":"1819","volume":"380","author":"Cohen","year":"2012"},{"key":"10.1016\/j.msard.2021.102945_bib0005","first-page":"1117","volume":"89","author":"Coles","year":"2017"},{"key":"10.1016\/j.msard.2021.102945_bib0006","first-page":"1829","volume":"380","author":"Coles","year":"2012"},{"key":"10.1016\/j.msard.2021.102945_bib0007","first-page":"1829","volume":"380","author":"Coles","year":"2012"},{"key":"10.1016\/j.msard.2021.102945_bib0008","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing\u2013remitting multiple sclerosis: the CLARITY Extension study. Ther","volume":"11","author":"Comi","year":"2018","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.102945_bib0009","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. Ther","volume":"11","author":"Comi","year":"2018","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.102945_bib0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102945_bib0011","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: The CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102945_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101504","article-title":"Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center","volume":"38","author":"di Ioia","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102945_bib0013","unstructured":"EMD Serono Research & Development Institute, n.d. Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis (MS) (CLASSIC-MS). ClinicalTrials.gov Identifier: NCT03961204."},{"key":"10.1016\/j.msard.2021.102945_bib0014","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00415-019-09272-6","article-title":"Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis","volume":"266","author":"Frau","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102945_bib0015","article-title":"The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study","volume":"3","author":"Freedman","year":"2017","journal-title":"Mult. Scler. J. \u2013 Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2021.102945_bib0016","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/cjn.2018.17","article-title":"Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. Can","volume":"45","author":"Freedman","year":"2018","journal-title":"J. Neurol. Sci. \/J. Can. des Sci. Neurol."},{"key":"10.1016\/j.msard.2021.102945_bib0017","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102945_bib0018","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102945_bib0019","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102945_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102619","article-title":"A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis","volume":"47","author":"Herman","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102945_bib0021","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s13104-019-4507-6","article-title":"Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis","volume":"12","author":"Holm\u00f8y","year":"2019","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.msard.2021.102945_bib0022","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","article-title":"Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings","volume":"3","author":"Kappos","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102945_bib0023","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology","volume":"9","author":"Koch-Henriksen","year":"2010","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2021.102945_bib0024","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/1352458506070931","article-title":"How similar are commonly combined criteria for EDSS progression in multiple sclerosis?","volume":"12","author":"Kragt","year":"2006","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102945_bib0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2021.102945_bib0026","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy","author":"Lizak","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102945_bib0027","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2021.102945_bib0028","series-title":"n.d. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)","author":"Mowry","year":"2018"},{"key":"10.1016\/j.msard.2021.102945_bib0029","series-title":"n.d. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)","author":"Ontaneda","year":"2018"},{"key":"10.1016\/j.msard.2021.102945_bib0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000158","article-title":"No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine","volume":"2","author":"Pakpoor","year":"2015","journal-title":"Neurol. Neuroimmunol. neuroinflammation"},{"key":"10.1016\/j.msard.2021.102945_bib0031","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther","volume":"13","author":"Patti","year":"2020","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.102945_bib0032","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/1352458519845110","article-title":"Commentary on \u2018Spontaneous multiple cervical artery dissections after alemtuzumab","volume":"26","author":"Pichler","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102945_bib0033","first-page":"1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial","volume":"54","author":"Rice","year":"2000","journal-title":"Cladribine MRI Study Group. Neurology"},{"key":"10.1016\/j.msard.2021.102945_bib0034","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2021.102945_bib0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40893-018-0037-7","article-title":"Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives","volume":"3","author":"Ruggieri","year":"2018","journal-title":"Mult. Scler. Demyelinating Disord."},{"key":"10.1016\/j.msard.2021.102945_bib0036","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.102945_bib0037","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.msard.2021.102945_bib0038","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","article-title":"Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223","volume":"267","author":"Steingo","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.102945_bib0039","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1352458509103610","article-title":"Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study","volume":"15","author":"Stelmasiak","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102945_bib0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2021.102945_bib0041","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1212\/WNL.0000000000008319","article-title":"Head-to-head drug comparisons in multiple sclerosis","volume":"93","author":"Tur","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102945_bib43","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/022561Orig1s000ClinPharmR.pdf. 2019. (Accessed 1 December 2020)."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:54:12Z","timestamp":1761900852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":42,"alternative-id":["S2211034821002121"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102945","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102945"}}